A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers

NCT06636877 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension
Type 2 Diabetes

Interventions

DRUG: BR1019
DRUG: BR1019-2
DRUG: BR1019-3

Sponsor

Boryung Pharmaceutical Co., Ltd